Stock listing
NASDAQ:IFRX InflaRx N.V. Stock
Home listing (NASDAQ) of InflaRx N.V.
Follow InflaRx N.V. into a list and get an email when it puts out news.
Share price · NASDAQ:IFRX
$1.66 USD -0.06 (-3.2%)
Close on Oct 30, 2026
- Day range
- $1.62 – $1.72 USDOct 30, 2026
- Volume
- 691,451 sharesOct 30, 2026
- Market cap
- $244.6M USDAt the close on Oct 30, 2026 · price × 147.4M shares outstanding
- 52-week range
- $0.798 – $2.95 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $1.44M USDMedian day 571,654 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IFRX · Home | $1.66 USD | -0.055 (-3.2%) | 691,451 | $1.71 | $1.72 | $1.621 | $1.715 | Close on Oct 30, 2026 |
| Frankfurt:IF0 | €1.396 EUR | +0.016 (+1.2%) | — | €1.501 | €1.501 | €1.396 | €1.38 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:IFRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.66 | -0.055 | -3.2% | $1.71 | $1.72 | $1.621 | 691,451 | |
| $1.715 | -0.015 | -0.9% | $1.74 | $1.79 | $1.71 | 306,538 | |
| $1.73 | +0.07 | +4.2% | $1.67 | $1.74 | $1.65 | 493,936 | |
| $1.66 | +0.085 | +5.4% | $1.59 | $1.66 | $1.57 | 513,063 | |
| $1.575 | +0.015 | +1.0% | $1.56 | $1.615 | $1.54 | 397,590 | |
| $1.56 | +0.03 | +2.0% | $1.51 | $1.585 | $1.48 | 889,583 | |
| $1.53 | -0.02 | -1.3% | $1.55 | $1.60 | $1.51 | 404,205 | |
| $1.55 | +0.01 | +0.6% | $1.55 | $1.61 | $1.54 | 701,424 | |
| $1.54 | +0.09 | +6.2% | $1.45 | $1.61 | $1.44 | 724,082 | |
| $1.45 | +0.13 | +9.8% | $1.33 | $1.48 | $1.285 | 2,806,396 | |
| $1.32 | -0.12 | -8.3% | $1.47 | $1.475 | $1.29 | 1,535,098 | |
| $1.44 | -0.04 | -2.7% | $1.47 | $1.53 | $1.43 | 552,043 | |
| $1.48 | -0.07 | -4.5% | $1.53 | $1.536 | $1.46 | 585,673 | |
| $1.55 | -0.04 | -2.5% | $1.59 | $1.605 | $1.54 | 367,525 | |
| $1.59 | -0.01 | -0.6% | $1.60 | $1.64 | $1.545 | 467,926 | |
| $1.60 | +0.07 | +4.6% | $1.55 | $1.695 | $1.546 | 740,708 | |
| $1.53 | -0.03 | -1.9% | $1.55 | $1.60 | $1.47 | 1,141,896 | |
| $1.56 | -0.02 | -1.3% | $1.60 | $1.60 | $1.55 | 460,353 | |
| $1.58 | -0.10 | -6.0% | $1.69 | $1.78 | $1.565 | 720,672 | |
| $1.68 | -0.04 | -2.3% | $1.70 | $1.72 | $1.65 | 701,007 | |
| $1.72 | +0.01 | +0.6% | $1.74 | $1.80 | $1.72 | 422,162 | |
| $1.71 | -0.09 | -5.0% | $1.83 | $1.856 | $1.71 | 369,955 | |
| $1.80 | -0.05 | -2.7% | $1.87 | $1.89 | $1.80 | 302,499 | |
| $1.85 | +0.03 | +1.6% | $1.83 | $1.89 | $1.80 | 268,404 | |
| $1.82 | -0.07 | -3.7% | $1.88 | $1.954 | $1.80 | 426,389 | |
| $1.89 | -0.04 | -2.1% | $1.94 | $2.04 | $1.87 | 399,901 | |
| $1.93 | -0.03 | -1.5% | $1.97 | $2.02 | $1.89 | 510,186 | |
| $1.96 | -0.12 | -5.8% | $2.08 | $2.09 | $1.96 | 564,758 | |
| $2.08 | -0.04 | -1.9% | $2.12 | $2.19 | $2.041 | 571,271 | |
| $2.12 | +0.03 | +1.4% | $2.11 | $2.19 | $2.065 | 345,149 | |
| $2.09 | +0.03 | +1.5% | $2.07 | $2.11 | $2.025 | 292,676 | |
| $2.06 | +0.02 | +1.0% | $2.05 | $2.10 | $1.98 | 657,951 | |
| $2.04 | +0.02 | +1.0% | $2.02 | $2.069 | $1.99 | 821,206 | |
| $2.02 | -0.10 | -4.7% | $2.12 | $2.165 | $1.99 | 579,599 | |
| $2.12 | +0.03 | +1.4% | $2.15 | $2.20 | $2.10 | 545,790 | |
| $2.09 | +0.04 | +2.0% | $2.07 | $2.11 | $2.04 | 334,148 | |
| $2.05 | -0.04 | -1.9% | $2.05 | $2.07 | $1.98 | 613,475 | |
| $2.09 | -0.08 | -3.7% | $2.15 | $2.15 | $2.05 | 759,750 | |
| $2.17 | -0.05 | -2.3% | $2.19 | $2.26 | $2.11 | 408,904 | |
| $2.22 | -0.01 | -0.4% | $2.21 | $2.377 | $2.16 | 393,942 | |
| $2.23 | -0.06 | -2.6% | $2.30 | $2.371 | $2.18 | 666,374 | |
| $2.29 | +0.13 | +6.0% | $2.16 | $2.34 | $2.133 | 572,036 | |
| $2.16 | +0.03 | +1.4% | $2.12 | $2.27 | $2.09 | 475,080 | |
| $2.13 | -0.10 | -4.5% | $2.21 | $2.23 | $2.09 | 447,811 | |
| $2.23 | -0.04 | -1.8% | $2.28 | $2.37 | $2.21 | 610,420 | |
| $2.27 | -0.15 | -6.2% | $2.40 | $2.435 | $2.245 | 1,405,954 | |
| $2.42 | -0.04 | -1.6% | $2.45 | $2.50 | $2.33 | 1,714,705 | |
| $2.46 | +0.41 | +20.0% | $2.06 | $2.46 | $2.01 | 3,894,358 | |
| $2.05 | -0.05 | -2.4% | $2.10 | $2.11 | $2.03 | 337,021 | |
| $2.10 | +0.08 | +4.0% | $2.03 | $2.12 | $2.025 | 419,898 | |
| $2.02 | -0.10 | -4.7% | $2.12 | $2.15 | $2.005 | 587,737 | |
| $2.12 | -0.06 | -2.8% | $2.18 | $2.22 | $2.09 | 958,323 | |
| $2.18 | +0.11 | +5.3% | $2.05 | $2.18 | $2.035 | 556,583 | |
| $2.07 | +0.03 | +1.5% | $2.04 | $2.095 | $2.03 | 564,830 | |
| $2.04 | +0.03 | +1.5% | $2.01 | $2.05 | $1.92 | 1,468,326 | |
| $2.01 | 0.00 | 0.0% | $2.02 | $2.055 | $1.965 | 1,898,952 | |
| $2.01 | +0.01 | +0.5% | $1.99 | $2.06 | $1.93 | 1,570,168 | |
| $2.00 | +0.04 | +2.0% | $1.99 | $2.02 | $1.92 | 491,390 | |
| $1.96 | +0.12 | +6.5% | $1.86 | $1.97 | $1.81 | 900,604 | |
| $1.84 | +0.12 | +7.0% | $1.81 | $1.905 | $1.78 | 1,167,415 | |
| $1.72 | -0.05 | -2.8% | $1.77 | $1.86 | $1.709 | 538,685 | |
| $1.77 | -0.01 | -0.6% | $1.76 | $1.81 | $1.745 | 710,044 | |
| $1.78 | +0.03 | +1.7% | $1.79 | $1.878 | $1.72 | 888,716 | |
| $1.75 | +0.05 | +2.9% | $1.68 | $1.76 | $1.675 | 557,847 | |
| $1.70 | -0.02 | -1.2% | $1.76 | $1.76 | $1.64 | 583,925 | |
| $1.72 | +0.07 | +4.2% | $1.68 | $1.735 | $1.65 | 1,113,985 |
- Ticker
- NASDAQ:IFRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 27, 2026
InflaRx Announces November Investor Events
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 37 slides
Latest news
InflaRx Announces November Investor Events
Oct 27, 2026
Closed $1.66 (+5.4%) on Oct 27, 2026
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Oct 22, 2026
Closed $1.53 (-1.3%) on Oct 22, 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Oct 2, 2026
Closed $1.72 (+0.6%) on Oct 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development
Oct 2, 2026
Closed $1.72 (+0.6%) on Oct 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Oct 1, 2026
Closed $1.71 (-5.0%) on Oct 1, 2026
InflaRx to Host Virtual Capital Markets Day
Sep 21, 2026
Closed $2.12 (+1.4%) on Sep 21, 2026
InflaRx Announces Participation in September Investor Conferences
Aug 20, 2026
Closed $2.02 (-4.7%) on Aug 20, 2026
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Aug 6, 2026
Closed $1.72 (-2.8%) on Aug 6, 2026
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Jul 30, 2026
Closed $1.72 (+4.2%) on Jul 30, 2026
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Jun 30, 2026
Closed $2.24 (-1.8%) on Jun 30, 2026
Decks
Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
Investor Presentation (May 2026)
Investor deck · 38 slides · May 6, 2026
Investor Presentation (May 2026)
Investor deck · 38 slides · May 2026
Investor Presentation (April 2026)
Investor deck · 67 slides · Apr 9, 2026
InflaRx N.V. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 116 in all · newest Oct 27, 2026 · oldest 2020
- Decks
- 25 decks · latest August 2026
Where InflaRx N.V. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IFRX · Home listing · This page | NASDAQ | United States | USD |
| Tradegate:IF0 | Tradegate | Germany | EUR |
| gettex:IF0 | gettex | Germany | EUR |
| LS Exchange:A2H7A5 | LS Exchange | Germany | EUR |
| Frankfurt:IF0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2H7A5 | Lang & Schwarz | Germany | EUR |
| Stuttgart:IF0 | Stuttgart | Germany | EUR |
| BOATS:IFRX | BOATS | United States | USD |
| BMV:IFRXN | BMV | Mexico | MXN |
| Munich:IF0 | Munich | Germany | EUR |
| BIVA:IFRXN | BIVA | Mexico | MXN |
| Dusseldorf:IF0 | Dusseldorf | Germany | EUR |
| Hamburg:IF0 | Hamburg | Germany | EUR |
Log in to ask 6ix AI your own questions about InflaRx N.V.